Generic Name: enzalutamide

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Astellas/Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Xtandi is an androgen receptor inhibitor approved for metastatic or nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant), as well as cancer that remains sensitive to testosterone-blocking therapy.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. To do so, they must bind to androgen receptors in prostate cells. Xtandi blocks signals from androgen receptors, preventing them from triggering cancer proliferation. It should be combined with drugs such as GnRH agonists that reduce testosterone production, known as androgen deprivation therapy (ADT).

The AFFIRM, PREVAIL and TERRAIN studies showed that Xtandi slows disease progression and improves survival of men with metastatic castration-resistant prostate cancer. The PROSPER study shows that Xtandi delays metastasis in men with nonmetastatic castration-resistant prostate cancer. THE ARCHES trial showed that the drug also delays progression of castration-sensitive prostate cancer.


Dosing Info:

Xtandi is taken as a pill. The usual dose is four capsules taken once daily with or without food.

Side Effects

Common side effects include fatigue, weakness, decreased appetite, weight loss, hot flashes, joint pain, dizziness or vertigo and high blood pressure. Seizures are a less common but potentially serious side effect. Xtandi has been associated with an increased risk of falling and bone fractures.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: December 17, 2019